Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan 15;11(1):93.
doi: 10.3390/cancers11010093.

Circulating Biomarkers for Prediction of Objective Response to Chemotherapy in Pancreatic Cancer Patients

Fleur van der Sijde  1 , Eveline E Vietsch  2 , Dana A M Mustafa  3 , Marc G Besselink  4 , Bas Groot Koerkamp  5 , Casper H J van Eijck  6
Affiliations
Review

Circulating Biomarkers for Prediction of Objective Response to Chemotherapy in Pancreatic Cancer Patients

Fleur van der Sijde et al. Cancers (Basel). .

Abstract

Pancreatic cancer is a lethal disease with increasing incidence. Most patients present with advanced disease, for which palliative systemic chemotherapy is the only therapeutic option. Despite improved median survival rates with FOLFIRINOX or gemcitabine chemotherapy compared to the best supportive care, many individual patients may not benefit from chemotherapy. Biomarkers are needed to predict who will benefit from chemotherapy and to monitor a patient's response to chemotherapy. This review summarizes current research and future perspectives on circulating biomarkers for systemic chemotherapy response.

Keywords: FOLFIRINOX; chemotherapy response; gemcitabine; pancreatic cancer; predictive circulating biomarker.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Rahib L., Smith B.D., Aizenberg R., Rosenzweig A.B., Fleshman J.M., Matrisian L.M. Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the united states. Cancer Res. 2014;74:2913–2921. doi: 10.1158/0008-5472.CAN-14-0155. - DOI - PubMed
    1. Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in globocan 2012. Int. J. Cancer. 2015;136:E359–E386. doi: 10.1002/ijc.29210. - DOI - PubMed
    1. Lau S.C., Cheung W.Y. Evolving treatment landscape for early and advanced pancreatic cancer. World J. Gastrointest. Oncol. 2017;9:281–292. doi: 10.4251/wjgo.v9.i7.281. - DOI - PMC - PubMed
    1. Christians K.K., Tsai S., Mahmoud A., Ritch P., Thomas J.P., Wiebe L., Kelly T., Erickson B., Wang H., Evans D.B., et al. Neoadjuvant folfirinox for borderline resectable pancreas cancer: A new treatment paradigm? Oncologist. 2014;19:266–274. doi: 10.1634/theoncologist.2013-0273. - DOI - PMC - PubMed
    1. Schwarz L., Vernerey D., Bachet J.B., Tuech J.J., Portales F., Michel P., Cunha A.S. Resectable pancreatic adenocarcinoma neo-adjuvant folf(irin)ox-based chemotherapy—A multicenter, non-comparative, randomized, phase ii trial (panache01-prodige48 study) BMC Cancer. 2018;18:762. doi: 10.1186/s12885-018-4663-4. - DOI - PMC - PubMed

LinkOut - more resources